Arachidonic acid: Physiological roles and potential health benefits – A review

Journal of Advanced Research

Volumn 11, Issue , 2018, Pages 33-41

  Tallima, Hatem ^a,b   El Ridi, Rashika ^a  

^a CAIRO UNIVERSITY   (Egypt)

^b The American University in Cairo   (Egypt)

Author keywords

Arachidonic acid; Endocannabinoids; Endotumoricide; Ion channels; Lipoxin A4; Schistosomicide

Indexed keywords

EID: 85036635057     PISSN: 20901232     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jare.2017.11.004     Document Type: Review

References (156)

1. Martin, S.A., Brash, A.R., Murphy, R.C., The discovery and early structural studies of arachidonic acid. J Lipid Res 57:7 (2016), 1126–1132.
2. Li, D., Ng, A., Mann, N.J., Sinclair, A.J., Contribution of meat fat to dietary arachidonic acid. Lipids 33:4 (1998), 437–440.
3. Taber, L., Chiu, C.H., Whelan, J., Assessment of the arachidonic acid content in foods commonly consumed in the American diet. Lipids 33:12 (1998), 1151–1157.
4. Komprda, T., Zelenka, J., Fajmonová, E., Fialová, M., Kladroba, D., Arachidonic acid and long-chain n-3 polyunsaturated fatty acid contents in meat of selected poultry and fish species in relation to dietary fat sources. J Agric Food Chem 53:17 (2005), 6804–6812.
5. Abedi, E., Sahari, M.A., Long-chain polyunsaturated fatty acid sources and evaluation of their nutritional and functional properties. Food Sci Nutr 2:5 (2014), 443–463.
6. Vance, J.E., Eukaryotic lipid-biosynthetic enzymes: the same but not the same. Trends Biochem Sci 23:11 (1998), 423–428.
7. Calder, P.C., Dietary arachidonic acid: harmful, harmless or helpful?. Br J Nutr 98:3 (2007), 451–453.
8. Pérez, R., Matabosch, X., Llebaria, A., Balboa, M.A., Balsinde, J., Blockade of arachidonic acid incorporation into phospholipids induces apoptosis in U937 promonocytic cells. J Lipid Res 47:3 (2006), 484–491.
9. Zhou, L., Xu, N., Nilsson, A., Tissue uptake and interconversion of plasma unesterified 14C linoleic acid in the guinea pig. Biochim Biophys Acta 1349:3 (1997), 197–210.
10. Zhou, L., Vessby, B., Nilsson, A., Quantitative role of plasma free fatty acids in the supply of arachidonic acid to extrahepatic tissues in rats. J Nutr 132:9 (2002), 2626–2631.
11. Sprecher, H., The roles of anabolic and catabolic reactions in the synthesis and recycling of polyunsaturated fatty acids. Prostaglandins Leukot Essent Fatty Acids 67:2–3 (2002), 79–83.
12. Huang, Y.-W., Huang, C.-Y., Gamma linolenic acid (GLA). Shahidi, F., (eds.) Nutraceutical and specialty lipids and their co-products, 2006, Taylor and Francis, Florida, 169–184 [chapter 10].
13. Wiktorowska-Owczarek, A., Berezińska, M., Nowak, J.Z., PUFAs: structures, metabolism and functions. Adv Clin Exp Med 24:6 (2015), 931–941.
14. Yamada, H., Shimizu, S., Shinmen, Y., Production of arachidonic acid by Mortierella elongata 1S-5. Agri Biol Chem 51:3 (1987), 785–790.
15. Aki, T., Nagahata, Y., Ishihara, K., Tanaka, Y., Morinaga, T., Higashiyama, K., et al. Production of arachidonic acid by a filamentous fungus, Mortierella alliacea strain YN-15. J Am Oil Chem Soc 78 (2001), 599–604.
16. Sakuradani, E., Shimizu, S., Single cell oil production by Mortierella alpina. J Biotechnol 144:1 (2009), 31–36.
17. Nisha, A., Rastogi, N.K., Venkateswaran, G., Optimization of media components for enhanced arachidonic acid production by Mortierella alpina under submerged cultivation. Biotechnol Bioprocess Eng 16 (2011), 229–237.
18. Wu, W.J., Zhang, A.H., Peng, C., Ren, L.J., Song, P., Yu, Y.D., et al. An efficient multi-stage fermentation strategy for the production of microbial oil rich in arachidonic acid in Mortierella alpina. Bioresour Bioprocess, 4(1), 2017, 8.
19. Grima, E., Perez, J., Camacho, F., Medina, A., Gimcnez, A., Lopez, Alonso D., The production of polyunsaturated fatty acids by microalgae: from strain selection to product purification. Process Biochem 30 (1995), 711–719.
20. Zhu, M., Zhou, P.P., Yu, L.J., Extraction of lipids from Mortierella alpina and enrichment of arachidonic acid from the fungal lipids. Bioresour Technol 84:1 (2002), 93–95.
21. You, J.-Y., Peng, C., Liu, X., Ji, X.-J., Lu, J., Tong, Q., et al. Enzymatic hydrolysis and extraction of arachidonic acid rich lipids from Mortierella alpina. Bioresour Technol 102:10 (2011), 6088–6094.
22. Ji, X.J., Ren, L.J., Nie, Z.K., Huang, H., Ouyang, P.K., Fungal arachidonic acid-rich oil: research, development and industrialization. Crit Rev Biotechnol 34:3 (2014), 197–214.
23. 2H3]-arachidonic acid. J Labelled Comp Radiopharm 27:5 (1989), 539–551.
24. Pompéia, C., Lopes, L.R., Miyasaka, C.K., Procópio, J., Sannomiya, P., Curi, R., Effect of fatty acids on leukocyte function. Braz J Med Biol Res 33:11 (2000), 1255–1268.
25. Brash, A.R., Arachidonic acid as a bioactive molecule. J Clin Invest 107:11 (2001), 1339–1345.
26. Beck, R., Bertolino, S., Abbot, S.E., Aaronson, P.I., Smirnov, S.V., Modulation of arachidonic acid release and membrane fluidity by albumin in vascular smooth muscle and endothelial cells. Circ Res 83:9 (1998), 923–931.
27. Söderberg, M., Edlund, C., Kristensson, K., Dallner, G., Fatty acid composition of brain phospholipids in aging and in Alzheimer's disease. Lipids 26:6 (1991), 421–425.
28. Kotani, S., Nakazawa, H., Tokimasa, T., Akimoto, K., Kawashima, H., Toyoda-Ono, Y., et al. Synaptic plasticity preserved with arachidonic acid diet in aged rats. Neurosci Res 46:4 (2003), 453–461.
29. Fukaya, T., Gondaira, T., Kashiyae, Y., Kotani, S., Ishikura, Y., Fujikawa, S., et al. Arachidonic acid preserves hippocampal neuron membrane fluidity in senescent rats. Neurobiol Aging 28:8 (2007), 1179–1186.
30. Tokuda, H., Kontani, M., Kawashima, H., Kiso, Y., Shibata, H., Osumi, N., Differential effect of arachidonic acid and docosahexaenoic acid on age-related decreases in hippocampal neurogenesis. Neurosci Res 88 (2014), 58–66.
31. Tokuda, H., Kontani, M., Kawashima, H., Akimoto, K., Kusumoto, A., Kiso, Y., et al. Arachidonic acid-enriched triacylglycerol improves cognitive function in elderly with low serum levels of arachidonic acid. J Oleo Sci 63:3 (2014), 219–227.
32. Swartz, K.J., Opening the gate in potassium channels. Nat Struct Mol Biol 11:6 (2004), 499–501.
33. Swartz, K.J., Towards a structural view of gating in potassium channels. Nat Rev Neurosci 5:12 (2004), 905–916.
34. Villarroel, A., Schwarz, T.L., Inhibition of the Kv4 (Shal) family of transient K+ currents by arachidonic acid. J Neurosci 16:8 (1996), 2522–2532.
35. Yazdi, S., Stein, M., Elinder, F., Andersson, M., Lindahl, E., The Molecular basis of polyunsaturated fatty acid interactions with the Shaker voltage-gated potassium channel. PLoS Comput Biol, 12(1), 2016, e1004704.
36. Yellen, G., The moving parts of voltage-gated ion channels. Q Rev Biophys. 31:3 (1998), 239–295.
37. Börjesson, S.I., Hammarström, S., Elinder, F., Lipoelectric modification of ion channel voltage gating by polyunsaturated fatty acids. Biophys J 95:5 (2008), 2242–2253.
38. Börjesson, S.I., Parkkari, T., Hammarström, S., Elinder, F., Electrostatic tuning of cellular excitability. Biophys J 98:3 (2010), 396–403.
39. Elinder, F., Liin, S.I., Actions and mechanisms of polyunsaturated fatty acids on voltage-gated ion channels. Front Physiol, 8, 2017, 43.
40. Horimoto, N., Nabekura, J., Ogawa, T., Arachidonic acid activation of potassium channels in rat visual cortex neurons. Neuroscience 77:3 (1997), 661–671.
41. Ordway RW, Walsh JV Jr, Singer JJ. Arachidonic acid and other fatty acids directly activate potassium channels in smooth muscle cells. Science 1989;244(4909):1176–9.
42. Ordway, R.W., Singer, J.J., Walsh, J.V. Jr., Direct regulation of ion channels by fatty acids. Trends Neurosci 14:3 (1991), 96–100.
43. Kirber, M.T., Ordway, R.W., Clapp, L.H., Walsh, J.V. Jr, Singer, J.J., Both membrane stretch and fatty acids directly activate large conductance Ca(2+)-activated K+ channels in vascular smooth muscle cells. FEBS Lett 297:1–2 (1992), 24–28.
44. Kuang, Q., Purhonen, P., Hebert, H., Structure of potassium channels. Cell Mol Life Sci 72:19 (2015), 3677–3693.
45. Denson, D.D., Wang, X., Worrell, R.T., Eaton, D.C., Effects of fatty acids on BK channels in GH(3) cells. Am J Physiol Cell Physiol 279:4 (2000), C1211–C1219.
46. Hamilton, K.L., Syme, C.A., Devor, D.C., Molecular localization of the inhibitory arachidonic acid binding site to the pore of hIK1. J Biol Chem 278:19 (2003), 16690–16697.
47. Patel, A.J., Lazdunski, M., Honoré, E., Lipid and mechano-gated 2P domain K(+) channels. Curr Opin Cell Biol 13:4 (2001), 422–428.
48. Kim, D., Fatty acid-sensitive two-pore domain K+ channels. Trends Pharmacol Sci 24:12 (2003), 648–654 [Review].
49. Kim, D., Duff, R.A., Regulation of K+ channels in cardiac myocytes by free fatty acids. Circ Res 67:4 (1990), 1040–1046.
50. Kang, J.X., Leaf, A., Prevention of fatal cardiac arrhythmias by polyunsaturated fatty acids. Am J Clin Nutr 71:1 Suppl (2000), 202S–207S.
51. Gu, H., Fang, Y.J., He, Y.L., Sun, J., Zhu, J., Mei, Y.A., Modulation of muscle rNaV1.4 Na+ channel isoform by arachidonic acid and its non-metabolized analog. J Cell Physiol 219:1 (2009), 173–182.
52. Tewari, K.P., Malinowska, D.H., Sherry, A.M., Cuppoletti, J., PKA and arachidonic acid activation of human recombinant ClC-2 chloride channels. Am J Physiol Cell Physiol 279:1 (2000), C40–C50.
53. Cuppoletti, J., Tewari, K.P., Sherry, A.M., Kupert, E.Y., Malinowska, D.H., ClC-2 Cl- channels in human lung epithelia: activation by arachidonic acid, amidation, and acid-activated omeprazole. Am J Physiol Cell Physiol 281:1 (2001), C46–C54.
54. Linsdell, P., Inhibition of cystic fibrosis transmembrane conductance regulator chloride channel currents by arachidonic acid. Can J Physiol Pharmacol 78:6 (2000), 490–499.
55. Zhou, J.J., Linsdell, P., Molecular mechanism of arachidonic acid inhibition of the CFTR chloride channel. Eur J Pharmacol 563:1–3 (2007), 88–91.
56. Kawanabe, A., Okamura, Y., Effects of unsaturated fatty acids on the kinetics of voltage-gated proton channels heterologously expressed in cultured cells. J Physiol 594:3 (2016), 595–610.
57. Nielsen, M., Witt, M.R., Thøgersen, H., [3H]diazepam specific binding to rat cortex in vitro is enhanced by oleic, arachidonic and docosahexenoic acid isolated from pig brain. Eur J Pharmacol 146:2–3 (1988), 349–353.
58. Witt, M.R., Westh-Hansen, S.E., Rasmussen, P.B., Hastrup, S., Nielsen, M., Unsaturated free fatty acids increase benzodiazepine receptor agonist binding depending on the subunit composition of the GABAA receptor complex. J Neurochem 67:5 (1996), 2141–2145.
59. Witt, M.R., Poulsen, C.F., Lükensmejer, B., Westh-Hansen, S.E., Nabekura, J., Akaike, N., et al. Structural requirements for the interaction of unsaturated free fatty acids with recombinant human GABAA receptor complexes. Ann N Y Acad Sci 868 (1999), 697–700.
60. Antollini SS, Barrantes FJ. Fatty acid regulation of voltage- and ligand-gated ion channel function. Front Physiol 2016;7:573 [eCollection 2016. Review].
61. Antollini, S.S., Barrantes, F.J., Unique effects of different fatty acid species on the physical properties of the torpedo acetylcholine receptor membrane. J Biol Chem 277:2 (2002), 1249–1254.
62. Nievas, G.A., Barrantes, F.J., Antollini, S.S., Conformation-sensitive steroid and fatty acid sites in the transmembrane domain of the nicotinic acetylcholine receptor. Biochemistry 46:11 (2007), 3503–3512.
63. Fernández Nievas, G.A., Barrantes, F.J., Antollini, S.S., Modulation of nicotinic acetylcholine receptor conformational state by free fatty acids and steroids. J Biol Chem 283:31 (2008), 21478–21486.
64. Pompéia, C., Cury-Boaventura, M.F., Curi, R., Arachidonic acid triggers an oxidative burst in leukocytes. Braz J Med Biol Res 36:11 (2003), 1549–1560.
65. Henderson, L.M., Thomas, S., Banting, G., Chappell, J.B., The arachidonate-activatable, NADPH oxidase-associated H+ channel is contained within the multi-membrane-spanning N-terminal region of gp91-phox. Biochem J 325:Pt 3 (1997), 701–705.
66. Henderson, L.M., Role of histidines identified by mutagenesis in the NADPH oxidase-associated H+ channel. J Biol Chem 273:50 (1998), 33216–33223.
67. Shiose, A., Sumimoto, H., Arachidonic acid and phosphorylation synergistically induce a conformational change of p47phox to activate the phagocyte NADPH oxidase. J Biol Chem 275:18 (2000), 13793–13801.
68. Jayadev, S., Linardic, C.M., Hannun, Y.A., Identification of arachidonic acid as a mediator of sphingomyelin hydrolysis in response to tumor necrosis factor alpha. J Biol Chem 269:8 (1994), 5757–5763.
69. Robinson, B.S., Hii, C.S., Poulos, A., Ferrante, A., Activation of neutral sphingomyelinase in human neutrophils by polyunsaturated fatty acids. Immunology 91:2 (1997), 274–280.
70. Hofmann, K., Tomiuk, S., Wolff, G., Stoffel, W., Cloning and characterization of the mammalian brain-specific, Mg2+-dependent neutral sphingomyelinase. Proc Natl Acad Sci USA 97:11 (2000), 5895–5900.
71. Huwiler, A., Kolter, T., Pfeilschifter, J., Sandhoff, K., Physiology and pathophysiology of sphingolipid metabolism and signaling. Biochim Biophys Acta 1485:2–3 (2000), 63–99.
72. Worgall, T.S., Johnson, R.A., Seo, T., Gierens, H., Deckelbaum, R.J., Unsaturated fatty acid-mediated decreases in sterol regulatory element-mediated gene transcription are linked to cellular sphingolipid metabolism. J Biol Chem 277:6 (2002), 3878–3885.
73. Marchesini, N., Hannun, Y.A., Acid and neutral sphingomyelinases: roles and mechanisms of regulation. Biochem Cell Biol 82:1 (2004), 27–44.
74. Tallima, H., Salah, M., El-Ridi, R., In vitro and in vivo effects of unsaturated fatty acids on Schistosoma mansoni and S. haematobium lung-stage larvae. J Parasitol 91:5 (2005), 1094–1102.
75. El Ridi, R., Tallima, H., Equilibrium in lung schistosomula sphingomyelin breakdown and biosynthesis allows very small molecules, but not antibody, to access proteins at the host-parasite interface. J Parasitol 92:4 (2006), 730–737.
76. Tallima, H., Al-Halbosiy, M.F., El Ridi, R., Enzymatic activity and immunolocalization of Schistosoma mansoni and Schistosoma haematobium neutral sphingomyelinase. Mol Biochem Parasitol 178:1–2 (2011), 23–28.
77. El Ridi, R., Tallima, H., Migliardo, F., Biochemical and biophysical methodologies open the road for effective schistosomiasis therapy and vaccination. Biochim Biophys Acta 1861:Pt B (2017), 3613–3620.
78. Chilton, F.H., Surette, M.E., Winkler, J.D., Arachidonate-phospholipid remodeling and cell proliferation. Adv Exp Med Biol 416 (1996), 169–172.
79. Surette, M.E., Fonteh, A.N., Bernatchez, C., Chilton, F.H., Perturbations in the control of cellular arachidonic acid levels block cell growth and induce apoptosis in HL-60 cells. Carcinogenesis 20:5 (1999), 757–763.
80. Cao, Y., Pearman, A.T., Zimmerman, G.A., McIntyre, T.M., Prescott, S.M., Intracellular unesterified arachidonic acid signals apoptosis. Proc Natl Acad Sci USA 97:21 (2000), 11280–11285.
81. Pompeia, C., Lima, T., Curi, R., Arachidonic acid cytotoxicity: can arachidonic acid be a physiological mediator of cell death?. Cell Biochem Funct 21:2 (2003), 97–104 [Review].
82. Innis, S.M., Impact of maternal diet on human milk composition and neurological development of infants. Am J Clin Nutr 99:3 (2014), 734S–741S.
83. Crawford, M.A., Costeloe, K., Ghebremeskel, K., Phylactos, A., Skirvin, L., Stacey, F., Are deficits of arachidonic and docosahexaenoic acids responsible for the neural and vascular complications of preterm babies?. Am J Clin Nutr 66:4 Suppl (1997), 1032S–1041S.
84. Senanayake, S.P.J.N., Jaouad Fichtali, J., Single-cell oils as sources of nutraceutical and specialty lipids: processing technologies and applications. Shahidi, F., (eds.) Nutraceutical and specialty lipids and their co-products, 2006, Taylor and Francis, Florida, 252–280 [chapter 16].
85. WHO and FAO joint consultation, Fats and oils in human nutrition. Nutr Rev 53:7 (1995), 202–205.
86. Tallima, H., Hadley, K., El Ridi, R., Praziquantel and arachidonic acid combination. Innovative approach to the treatment of Schistosomiasis. Amidou, S., (eds.) An overview of tropical diseases, 2015, InTech, Rijeka, 145–172.
87. Hadley, K.B., Ryan, A.S., Forsyth, S., Gautier, S., Salem, N. Jr., The Essentiality of arachidonic acid in infant development. Nutrients, 8(4), 2016, 216.
88. Robinson, D.T., Martin, C.R., Fatty acid requirements for the preterm infant. Semin Fetal Neonatal Med 22:1 (2017), 8–14.
89. EFSA Panel on Dietetic Products, Nutrition and Allergies. Scientific Opinion on the essential composition of infant and follow-on formulae. EFSA J, 12(7), 2014, 3760.
90. Salem, N. Jr, Wegher, B., Mena, P., Uauy, R., Arachidonic and docosahexaenoic acids are biosynthesized from their 18-carbon precursors in human infants. Proc Natl Acad Sci USA 93:1 (1996), 49–54.
91. Rapoport, S.I., Arachidonic acid and the brain. J Nutr 138:12 (2008), 2515–2520.
92. Crawford, M.A., Golfetto, I., Ghebremeskel, K., Min, Y., Moodley, T., Poston, L., et al. The potential role for arachidonic and docosahexaenoic acids in protection against some central nervous system injuries in preterm infants. Lipids 38:4 (2003), 303–315 [Review].
93. Meguid, N.A., Atta, H.M., Gouda, A.S., Khalil, R.O., Role of polyunsaturated fatty acids in the management of Egyptian children with autism. Clin Biochem 41:13 (2008), 1044–1048.
94. Yui, K., Koshiba, M., Nakamura, S., Kobayashi, Y., Effects of large doses of arachidonic acid added to docosahexaenoic acid on social impairment in individuals with autism spectrum disorders: a double-blind, placebo-controlled, randomized trial. J Clin Psychopharmacol 32:2 (2012), 200–206.
95. Baur, L.A., O'Connor, J., Pan, D.A., Kriketos, A.D., Storlien, L.H., The fatty acid composition of skeletal muscle membrane phospholipid: its relationship with the type of feeding and plasma glucose levels in young children. Metabolism 47:1 (1998), 106–112.
96. Salem, N.M., Lin, Y.H., Moriguchi, T., Lim, S.Y., Salem, N. Jr, Hibbeln, J.R., Distribution of omega-6 and omega-3 polyunsaturated fatty acids in the whole rat body and 25 compartments. Prostaglandins Leukot Essent Fatty Acids 100 (2015), 13–20.
97. El Ridi, R., Mohamed, S.H., Tallima, H., Incubation of Schistosoma mansoni lung-stage schistosomula in corn oil exposes their surface membrane antigenic specificities. J Parasitol 89:5 (2003), 1064–1067.
98. El Ridi, R.A., Tallima, H.A., Novel therapeutic and prevention approaches for schistosomiasis: review. J Adv Res 4:5 (2013), 467–478.
99. Othman, A., El Ridi, R., Schistosomiasis. Bruschi, F., (eds.) Helminth infections and their impact on global public health, 2014, Springer, Heidelberg, 49–92.
100. El Ridi, R., Aboueldahab, M., Tallima, H., Salah, M., Mahana, N., Fawzi, S., et al. In vitro and in vivo activities of arachidonic acid against Schistosoma mansoni and Schistosoma haematobium. Antimicrob Agents Chemother 54:8 (2010), 3383–3389.
101. El Ridi, R., Tallima, H., Salah, M., Aboueldahab, M., Fahmy, O.M., Al-Halbosiy, M.F., et al. Efficacy and mechanism of action of arachidonic acid in the treatment of hamsters infected with Schistosoma mansoni or Schistosoma haematobium. Int J Antimicrob Agents 39:3 (2012), 232–239.
102. Selim, S., El Sagheer, O., El Amir, A., Barakat, R., Hadley, K., Bruins, M.J., et al. Efficacy and safety of arachidonic acid for treatment of Schistosoma mansoni-infected children in Menoufiya, Egypt. Am J Trop Med Hyg 91:5 (2014), 973–981.
103. Barakat, R., Abou El-Ela, N.E., Sharaf, S., El Sagheer, O., Selim, S., Tallima, H., et al. Efficacy and safety of arachidonic acid for treatment of school-age children in Schistosoma mansoni high-endemicity regions. Am J Trop Med Hyg 92:4 (2015), 797–804.
104. Amaral, K.B., Silva, T.P., Malta, K.K., Carmo, L.A., Dias, F.F., Almeida, M.R., et al. Natural Schistosoma mansoni infection in the wild reservoir Nectomys squamipes leads to excessive lipid droplet accumulation in hepatocytes in the absence of liver functional impairment. PLoS ONE, 11(11), 2016, e0166979.
105. Hanna, V.S., Gawish, A., Abou El Dahab, M., Tallima, H., El Ridi, R., Is arachidonic acid an endoschistosomicide?. J Adv Res 11 (2018), 81–89.
106. El-Faham, M.H., Eissa, M.M., Igetei, J.E., Amer, E.I., Liddell, S., El-Azzouni, M.Z., et al. Treatment of Schistosoma mansoni with miltefosine in vitro enhances serological recognition of defined worm surface antigens. PLoS Negl Trop Dis, 11(8), 2017, e0005853.
107. Siegel, I., Liu, T.L., Yaghoubzadeh, E., Keskey, T.S., Gleicher, N., Cytotoxic effects of free fatty acids on ascites tumor cells. J Natl Cancer Inst 78:2 (1987), 271–277.
108. Das, U.N., Gamma-linolenic acid, arachidonic acid, and eicosapentaenoic acid as potential anticancer drugs. Nutrition 6:6 (1990), 429–434.
109. Das, U.N., Tumoricidal action of cis-unsaturated fatty acids and their relationship to free radicals and lipid peroxidation. Cancer Lett 56:3 (1991), 235–243.
110. Sagar, P.S., Das, U.N., Cytotoxic action of cis-unsaturated fatty acids on human cervical carcinoma (HeLa) cells in vitro. Prostaglandins Leukot Essent Fatty Acids 53:4 (1995), 287–299.
111. Ramesh, G., Das, U.N., Effect of cis-unsaturated fatty acids on Meth-A ascitic tumour cells in vitro and in vivo. Cancer Lett 123:2 (1998), 207–214.
112. Das, U.N., Madhavi, N., Effect of polyunsaturated fatty acids on drug-sensitive and resistant tumor cells in vitro. Lipids Health Dis, 10, 2011, 159.
113. Dai, J., Shen, J., Pan, W., Shen, S., Das, U.N., Effects of polyunsaturated fatty acids on the growth of gastric cancer cells in vitro. Lipids Health Dis, 12, 2013, 71.
114. Meng, H., Shen, Y., Shen, J., Zhou, F., Shen, S., Das, U.N., Effect of n-3 and n-6 unsaturated fatty acids on prostate cancer (PC-3) and prostate epithelial (RWPE-1) cells in vitro. Lipids Health Dis, 12, 2013, 160.
115. Zhang, C., Yu, H., Shen, Y., Ni, X., Shen, S., Das, U.N., Polyunsaturated fatty acids trigger apoptosis of colon cancer cells through a mitochondrial pathway. Arch Med Sci 11:5 (2015), 1081–1094.
116. Petrik, M.B., McEntee, M.F., Chiu, C.H., Whelan, J., Antagonism of arachidonic acid is linked to the antitumorigenic effect of dietary eicosapentaenoic acid in Apc(Min/+) mice. J Nutr 130:5 (2000), 1153–1158.
117. Arenz, C., Giannis, A., Synthesis of the first selective irreversible inhibitor of neutral sphingomyelinase. Angew Chem Int Ed Engl 39:8 (2000), 1440–1442.
118. Colombo, D.T., Tran, L.K., Speck, J.J., Reitz, R.C., Comparison of hexadecyl phosphocholine with fish oil as an antitumor agent. J Lipid Mediat Cell Signal 17:1 (1997), 47–63.
119. Wieder, T., Orfanos, C.E., Geilen, C.C., Induction of ceramide-mediated apoptosis by the anticancer phospholipid analog, hexadecylphosphocholine. J Biol Chem 273:18 (1998), 11025–11031.
120. Jiménez-López, J.M., Carrasco, M.P., Marco, C., Segovia, J.L., Hexadecylphospho-choline disrupts cholesterol homeostasis and induces the accumulation of free cholesterol in HepG2 tumour cells. Biochem Pharmacol 71:8 (2006), 1114–1121.
121. Marco, C., Jiménez-López, J.M., Ríos-Marco, P., Segovia, J.L., Carrasco, M.P., Hexadecylphosphocholine alters nonvesicular cholesterol traffic from the plasma membrane to the endoplasmic reticulum and inhibits the synthesis of sphingomyelin in HepG2 cells. Int J Biochem Cell Biol 41:6 (2009), 1296–1303.
122. Korotkova, M., Jakobsson, P.J., Persisting eicosanoid pathways in rheumatic diseases. Nat Rev Rheumatol 10:4 (2014), 229–241.
123. Korotkova, M., Lundberg, I.E., The skeletal muscle arachidonic acid cascade in health and inflammatory disease. Nat Rev Rheumatol 10:5 (2014), 295–303.
124. Esser-von, Bieren J., Immune-regulation and functions of eicosanoid lipid mediators. Biol Chem 398:11 (2017), 1177–1191.
125. Maderna, P., Godson, C., Lipoxins: resolutionary road. Br J Pharmacol 158:4 (2009), 947–959.
126. Serhan, C.N., Chiang, N., Resolution phase lipid mediators of inflammation: agonists of resolution. Curr Opin Pharmacol 13 (2013), 632–640.
127. Serhan, C.N., Pro-resolving lipid mediators are leads for resolution physiology. Nature 510:7503 (2014), 92–101.
128. Serhan, C.N., Chiang, N., Dalli, J., The resolution code of acute inflammation: novel pro-resolving lipid mediators in resolution. Semin Immunol 27:3 (2015), 200–215.
129. Börgeson, E., McGillicuddy, F.C., Harford, K.A., Corrigan, N., Higgins, D.F., Maderna, P., et al. Lipoxin A4 attenuates adipose inflammation. FASEB J 26:10 (2012), 4287–4294.
130. Reis, M.B., Pereira, P.A.T., Caetano, G.F., Leite, M.N., Galvão, A.F., Paula-Silva, F.W.G., et al. Lipoxin A4 encapsulated in PLGA microparticles accelerates wound healing of skin ulcers. PLoS ONE, 12(7), 2017, e0182381.
131. 4: a new direction in asthma therapy?. Expert Rev Clin Immunol 9:6 (2013), 491–493.
132. Barnig, C., Cernadas, M., Dutile, S., Liu, X., Perrella, M.A., Kazani, S., et al. Lipoxin A4 regulates natural killer cell and type 2 innate lymphoid cell activation in asthma. Sci Transl Med, 5(174), 2013, 174ra26.
133. Pozzi, A., Zent, R., Regulation of endothelial cell functions by basement membrane- and arachidonic acid-derived products. Wiley Interdiscip Rev Syst Biol Med 1:2 (2009), 254–272.
134. Berry, E., Liu, Y., Chen, L., Guo, A.M., Eicosanoids: emerging contributors in stem cell-mediated wound healing. Prostaglandins Other Lipid Mediat 132 (2017), 17–24.
135. Das, U.N., Arachidonic acid and lipoxin A4 as possible endogenous anti-diabetic molecules. Prostaglandins Leukot Essent Fatty Acids 88:3 (2013), 201–210.
136. Das, U.N., Is there a role for bioactive lipids in the pathobiology of diabetes mellitus?. Front Endocrinol (Lausanne), 8, 2017, 182.
137. Bisogno, T., Maccarrone, M., Endocannabinoid signaling and its regulation by nutrients. BioFactors 40:4 (2014), 373–380.
138. Wei, D., Lee, D., Li, D., Daglian, J., Jung, K.M., Piomelli, D., A role for the endocannabinoid 2-arachidonoyl-sn-glycerol for social and high-fat food reward in male mice. Psychopharmacology 233:10 (2016), 1911–1919.
139. Wei, D., Allsop, S., Tye, K., Piomelli, D., Endocannabinoid signaling in the control of social behavior. Trends Neurosci 40:7 (2017), 385–396.
140. Piomelli, D., The endocannabinoid system: a drug discovery perspective. Curr Opin Investig Drugs 6:7 (2005), 672–679.
141. More surprises lying ahead, The endocannabinoids keep us guessing. Neuropharmacology 76:Pt B (2014), 228–234.
142. Amoako, A.A., Marczylo, T.H., Marczylo, E.L., Elson, J., Willets, J.M., Taylor, A.H., et al. Anandamide modulates human sperm motility: implications for men with asthenozoospermia and oligoasthenoteratozoospermia. Hum Reprod 28:8 (2013), 2058–2066.
143. Alhouayek, M., Muccioli, G.G., The endocannabinoid system in inflammatory bowel diseases: from pathophysiology to therapeutic opportunity. Trends Mol Med 18:10 (2012), 615–625.
144. Izzo, A.A., Muccioli, G.G., Ruggieri, M.R., Schicho, R., Endocannabinoids and the digestive tract and bladder in health and disease. Handb Exp Pharmacol 231 (2015), 423–447.
145. Moradi, H., Oveisi, F., Khanifar, E., Moreno-Sanz, G., Vaziri, N.D., Piomelli, D., Increased renal 2-arachidonoylglycerol level is associated with improved renal function in a mouse model of acute kidney injury. Cannabis Cannabinoid Res 1:1 (2016), 218–228.
146. Klose, C.S., Artis, D., Innate lymphoid cells as regulators of immunity, inflammation and tissue homeostasis. Nat Immunol 17:7 (2016), 765–774.
147. Tait Wojno, E.D., Artis, D., Emerging concepts and future challenges in innate lymphoid cell biology. J Exp Med 213:11 (2016), 2229–2248.
148. Halim, T.Y., Group 2 innate lymphoid cells in disease. Int Immunol 28:1 (2016), 13–22.
149. Hanna, V.S., Hafez, E.A., Synopsis of arachidonic acid metabolism- A review. J Adv Res 11 (2018), 23–32.
150. Doherty, T.A., Khorram, N., Lund, S., Mehta, A.K., Croft, M., Broide, D.H., Lung type 2 innate lymphoid cells express cysteinyl leukotriene receptor 1, which regulates TH2 cytokine production. J Allergy Clin Immunol 132:1 (2013), 205–213.
151. Xue, L., Salimi, M., Panse, I., Mjösberg, J.M., McKenzie, A.N., Spits, H., et al. Prostaglandin D2 activates group 2 innate lymphoid cells through chemoattractant receptor-homologous molecule expressed on TH2 cells. J Allergy Clin Immunol 133:4 (2014), 1184–1194.
152. Wojno, E.D., Monticelli, L.A., Tran, S.V., Alenghat, T., Osborne, L.C., Thome, J.J., et al. The prostaglandin D₂ receptor CRTH2 regulates accumulation of group 2 innate lymphoid cells in the inflamed lung. Mucosal Immunol 8:6 (2015), 1313–1323.
153. Xue, L., Fergusson, J., Salimi, M., Panse, I., Ussher, J.E., Hegazy, A.N., et al. Prostaglandin D2 and leukotriene E4 synergize to stimulate diverse TH2 functions and TH2 cell/neutrophil crosstalk. J Allergy Clin Immunol 135:5 (2015), 1358–1366.
154. Salimi, M., Stöger, L., Liu, W., Go, S., Pavord, I., Klenerman, P., et al. Cysteinyl leukotriene E4 activates human group 2 innate lymphoid cells and enhances the effect of prostaglandin D2 and epithelial cytokines. J Allergy Clin Immunol 140:4 (2017), 1090–1100.
155. Lund, S.J., Portillo, A., Cavagnero, K., Baum, R.E., Naji, L.H., Badrani, J.H., et al. Leukotriene C4 potentiates IL-33-induced group 2 innate lymphoid cell activation and lung inflammation. J Immunol 199:3 (2017), 1096–1104.
156. Halim, T.Y., Hwang, Y.Y., Scanlon, S.T., Zaghouani, H., Garbi, N., Fallon, P.G., et al. Group 2 innate lymphoid cells license dendritic cells to potentiate memory TH2 cell responses. Nat Immunol 17:1 (2016), 57–64.